A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of AKR-001 in Subjects with Nonalcoholic Steatohepatitis (NASH)

The primary objective of this study is to evaluate absolute change from baseline in hepatic fat fraction assessed by Magnetic Resonance Imaging – Proton Density Fat Fraction (MRI-PDFF) at Week 12